DaVita (NYSE:DVA) Shares Gap Down – Here’s What Happened

DaVita Inc. (NYSE:DVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $227.99, but opened at $205.25. DaVita shares last traded at $189.97, with a volume of 1,002,727 shares changing hands.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported second-quarter adjusted EPS of $4.02, above the roughly $3.88–$4.01 analyst consensus, while revenue reached $3.554 billion, ahead of expectations and up 5.2% year over year. Adjusted operating income was $579 million and free cash flow was $256 million. DaVita Inc. 2nd Quarter 2026 Results
• Positive Sentiment: Management highlighted clinical-led treatment-volume growth, improved patient outcomes and broader access to “middle molecule” therapies as factors supporting future performance. The company also maintained its strategic focus on dialysis innovation. DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
• Positive Sentiment: Barclays raised its price target from $218 to $224, although it retained an “equal weight” rating. Unusually high call-option activity also indicates increased speculative interest in DVA. Barclays Price Target Update
• Neutral Sentiment: DaVita reaffirmed 2026 adjusted EPS guidance of $14.10–$15.20, adjusted operating income of $2.15–$2.25 billion and free cash flow of $1.0–$1.25 billion. The midpoint remains close to analyst expectations, but management did not raise the outlook after a strong quarter.
• Negative Sentiment: U.S. dialysis revenue per treatment declined sequentially to $415.87 from $417.59, reflecting payer-mix changes and normal fluctuations. Investors also noted higher general and administrative expenses and ongoing reimbursement pressure.
• Negative Sentiment: The market reaction suggests expectations had been elevated ahead of earnings: the earnings and revenue beats were not enough to offset disappointment over the lack of a guidance increase. DaVita Slides as Solid Q2 Results Fail to Lift Full-Year Outlook

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Barclays raised their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday. Truist Financial raised their price target on shares of DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of DaVita in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus target price of $217.50.

DaVita Trading Down 19.3%

The company has a market cap of $11.81 billion, a P/E ratio of 17.07, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88. The company’s fifty day moving average is $219.11 and its 200 day moving average is $175.36.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the firm posted $2.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts anticipate that DaVita Inc. will post 15.07 EPS for the current year.

Insider Transactions at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after buying an additional 636,191 shares during the last quarter. Norges Bank bought a new stake in DaVita in the 4th quarter worth $49,164,000. Corient Private Wealth LLC grew its holdings in DaVita by 1,493.1% in the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after acquiring an additional 335,809 shares during the last quarter. Man Group plc increased its position in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares during the period. Finally, Voloridge Investment Management LLC increased its position in shares of DaVita by 2,905.7% in the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock valued at $30,324,000 after acquiring an additional 220,628 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.